Phase 2 N=143 Randomized Double-blind Treatment

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

Gout · Hyperuricemia

Bottom Line

View on ClinicalTrials.gov: NCT03934099 ↗

Enrolled (actual)

143

Serious AEs

0.0%

Results posted

Dec 2025

Primary outcome: Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: LC350189 formulated capsule (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: LG Chem
Primary completion: May 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84	47.1; 44.7; 62.2; 2.9	—
SECONDARY Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84	58.8; 63.2; 78.4; 2.9	—
SECONDARY Maximum Percent Reduction in sUA (Serum Uric Acid) Level	-46.67; -50.64; -66.79; -11.20	—

Summary

The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

Eligibility Criteria

Inclusion Criteria

Subjects or the subject's legally acceptable representatives who sign a written informed consent form prior to the initiation of any study procedures.
Subjects with hyperuricemia and a history or presence of gout per American College of Rheumatology (ACR) criteria.

Exclusion Criteria

Subjects with secondary hyperuricemia (e.g., due to myeloproliferative disorder, or organ transplant).
Subjects experiencing an active acute gout attack within 3 weeks prior to screening (Visit 1).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03934099). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.